DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l297t2/gastrointestinal) has announced the addition of the "Global Gastrointestinal Tumor - Pipeline Review - H2 2013" report to their offering.
'Gastrointestinal Tumor - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for gastrointestinal tumor.
The analysis is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- A snapshot of the global therapeutic scenario for Gastrointestinal Tumor.
- A review of the Gastrointestinal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
-
Coverage of the Gastrointestinal Tumor pipeline on the basis of route
of administration and molecule type.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
Key Topics Covered:
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Gastrointestinal Tumor Overview
Therapeutics Development
Companies Involved in Gastrointestinal Tumor Therapeutics Development
Drug Profiles
- DG-3173
- (tipiracil hydrochloride + trifluridine)
- paclitaxel
- bevacizumab
-
MGD-007
Featured News & Press Releases
Appendix
Companies Mentioned
- CritiTech.
- F. Hoffmann-La Roche
- MacroGenics
- Nobelpharma Co
- Taiho Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/l297t2/gastrointestinal
